CLAIMS

1. The use of a class I histone deacetylase activity inhibitor in the manufacture of a medicament for inhibiting covalently closed circular DNA (cccDNA) transcription of hepatitis B virus, wherein said histone deacetylase activity inhibitor is selected from the group consisting of Trichostatin A, suberoyl bis hydroxamic acid, 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl] benzamide, and Apicidin, or a pharmaceutically acceptable salt thereof.

2. The use according to claim 1, wherein said histone deacetylase activity inhibitor is Apicidin, or a pharmaceutically acceptable salt thereof.

3. The use according to claim 1, further wherein the medicament further comprises a therapeutically effective amount of an additional anti hepatitis B infection agent.

4. The use of a class I histone deacetylase activity inhibitor in the manufacture of a medicament for treating hepatitis B, wherein said histone deacetylase activity inhibitor is selected from the group consisting of Trichostatin A, suberoyl bis hydroxamic acid, 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl] benzamide, and Apicidin, or a pharmaceutically acceptable salt thereof.

5. The use according to claim 4, wherein said histone deacetylase activity inhibitor is Apicidin, or a pharmaceutically acceptable salt thereof.

6. The use according to claim 4, further wherein the medicament further comprises a therapeutically effective amount of an additional anti hepatitis B infection agent.

7. The use of a class I histone deacetylase activity inhibitor in the manufacture of a medicament for repressing hepatitis B virus covalently closed circular DNA, wherein said histone deacetylase activity inhibitor is selected from the group consisting of Trichostatin A, suberoyl bis hydroxamic acid, 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl] benzamide, and Apicidin, or a pharmaceutically acceptable salt thereof.

8. The use according to claim 7, wherein said histone deacetylase activity inhibitor is Apicidin, or a pharmaceutically acceptable salt thereof.

9. The use according to claim 7, further wherein the medicament further comprises a therapeutically effective amount of an additional anti hepatitis B infection agent.